Skip to main content
×
×
Home

Melatonin and its agonists: an update

  • Josephine Arendt (a1) and Shantha M. W. Rajaratnam (a2)
Summary

The pineal hormone melatonin is able to shift the timing of circadian rhythms, including the sleep–wake cycle, and to promote sleep. Melatonin agonists with similar properties have therapeutic potential for the treatment of circadian rhythm sleep disorders. Depression is specifically targeted by agomelatine, which is also a serotonin-2C (5-HT2C) antagonist.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Melatonin and its agonists: an update
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Melatonin and its agonists: an update
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Melatonin and its agonists: an update
      Available formats
      ×
Copyright
Corresponding author
Josephine Arendt, Centre for Chronobiology, School of Biomedical and Molecular Sciences, University of Surrey, Guildford, Surrey GU2 7XH, UK. Email: ArendtJo@aol.com
Footnotes
Hide All

Declaration of interest

S.M.W.R has received research funding and unrestricted educational grants from Vanda Pharmaceuticals (developers of tasimelteon) and Takeda Pharmaceuticals North America (developers of ramelteon). J.A. is a consultant to Alliance Pharmaceuticals, UK (currently developing melatonin formulations). She is a director of Stockgrand Ltd, University of Surrey, UK, a company that sells measurement technology for melatonin and other substances.

Footnotes
References
Hide All
1 Arendt, J. Melatonin: characteristics, concerns, and prospects. J Biol Rhythms 2005; 20: 291303.
2 Wehr, TA, Duncan, WC Jr, Sher, L, Aeschbach, D, Schwartz, PJ, Turner, EH, Postolache, TT, Rosenthal, NE. A circadian signal of change of season in patients with seasonal affective disorder. Arch Gen Psychiatry 2001; 58: 1108–14.
3 Rajaratnam, SMW, Arendt, J. Health in the 24-hour society. Lancet 2001; 358: 9991005.
4 Dijk, DJ, Lockley, SW. Integration of human sleep-wake regulation and circadian rhythmicity (Invited Review). J Appl Physiol 2002; 92: 852–62.
5 Lewy, AJ, Lefler, BJ, Emens, JS, Bauer, VK. The circadian basis of winter depression. Proc Natl Acad Sci USA 2006; 103: 7414–9.
6 Rajaratnam, SM, Middleton, B, Stone, BM, Arendt, J, Dijk, DJ. Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans. J Physiol 2004; 561 (Pt 1): 339–51.
7 Serfaty, MA, Osborne, D, Buszewicz, MJ, Raven, PW. The effects of exogenous melatonin in major depression. Chronobiol Int 2003; 20: 1191–3.
8 Dubocovich, ML. Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Med 2007; 8 (suppl 3): 3442.
9 Nickelsen, T, Samel, A, Vejvoda, M, Wenzel, J, Smith, B, Gerzer, R. Chronobiotic effects of the melatonin agonist LY 156735 following a simulated 9h time shift: results of a placebo-controlled trial. Chronobiol Int 2002; 19: 915–36.
10 Zemlan, FP, Mulchahey, JJ, Scharf, MB, Mayleben, DW, Rosenberg, R, Lankford, A. The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry 2005; 66: 384–90.
11 Montgomery, SA. Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist. Eur Neuropsychopharmacol 2006; 16: s6338.
12 Olie, JP, Kasper, S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10: 661–73.
13 Lemoine, P, Guilleminault, C, Alvarez, E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68: 1723–32.
14 Goodwin, GM. Effective management of depressed mood with agomelatine, a melatonergic antidepressant Eur Psychiatry 2007; 22 (suppl 1): s91.
15 Hirai, K, Kita, M, Ohta, H, Nishikawa, H, Fujiwara, Y, Ohkawa, S, Miyamoto, M. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms 2005; 20: 2737.
16 Borja, NL, Daniel, KL. Ramelteon for the treatment of insomnia. Clin Ther 2006; 28: 1540–55.
17 Vachharajani, NN, Yeleswaram, K, Boulton, DW. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. J Pharm Sci 2003; 92: 760–72.
18 Rajaratnam, SM, Polymeropoulos, MH, Fisher, DM, Roth, T, Scott, C, Birznieks, G, Klerman, EB. Randomised controlled trials of the melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep time shift. Lancet, in press.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 17 *
Loading metrics...

Abstract views

Total abstract views: 96 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 27th April 2018. This data will be updated every 24 hours.

Melatonin and its agonists: an update

  • Josephine Arendt (a1) and Shantha M. W. Rajaratnam (a2)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *